74 related articles for article (PubMed ID: 30405212)
1. Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?
Calcagno A; Fiumanò M; Zugna D; Cusato J; Montrucchio C; Marinaro L; Trentini L; Ferrara M; D'Avolio A; Pizzi C; Di Perri G; Bonora S
Pharmacogenomics J; 2019 Feb; 19(1):65-71. PubMed ID: 30405212
[TBL] [Abstract][Full Text] [Related]
2. Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.
Lee KH; Lee JU; Ku NS; Jeong SJ; Han SH; Choi JY; Song YG; Kim JM
Yonsei Med J; 2017 Jul; 58(4):770-777. PubMed ID: 28540990
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana.
Chadwick DR; Sarfo FS; Kirk ES; Owusu D; Bedu-Addo G; Parris V; Owusu AL; Phillips R
BMC Nephrol; 2015 Dec; 16():195. PubMed ID: 26627687
[TBL] [Abstract][Full Text] [Related]
4. HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study.
Jotwani V; Scherzer R; Estrella MM; Jacobson LP; Witt MD; Palella FJ; Macatangay B; Bennett M; Parikh CR; Ix JH; Shlipak MG
Am J Kidney Dis; 2016 Oct; 68(4):571-581. PubMed ID: 27287300
[TBL] [Abstract][Full Text] [Related]
5. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
[TBL] [Abstract][Full Text] [Related]
6. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir.
Casado JL; Bañón S; Santiuste C; Serna J; Guzman P; Tenorio M; Liaño F; del Rey JM
AIDS; 2016 Jan; 30(2):231-9. PubMed ID: 26684820
[TBL] [Abstract][Full Text] [Related]
8. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
Decloedt EH; Lesosky M; Maartens G; Joska JA
AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772
[TBL] [Abstract][Full Text] [Related]
9. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
Boyd A; Bottero J; Miailhes P; Lascoux-Combe C; Rougier H; Girard PM; Serfaty L; Lacombe K
J Int AIDS Soc; 2017 Feb; 20(1):21426. PubMed ID: 28362068
[TBL] [Abstract][Full Text] [Related]
10. Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy.
Nishijima T; Kurosawa T; Tanaka N; Kawasaki Y; Kikuchi Y; Oka S; Gatanaga H
AIDS; 2016 Jun; 30(10):1563-71. PubMed ID: 26919734
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
[TBL] [Abstract][Full Text] [Related]
12. Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
Guillemi SA; Ling SH; Dahlby JS; Yip B; Zhang W; Hull MW; Lima VD; Hogg RS; Werb R; Montaner JS; Harris M
J Int AIDS Soc; 2016; 19(1):20995. PubMed ID: 27624144
[TBL] [Abstract][Full Text] [Related]
13. Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation.
Yoshino M; Yagura H; Kushida H; Yonemoto H; Bando H; Ogawa Y; Yajima K; Kasai D; Taniguchi T; Watanabe D; Nishida Y; Kuwahara T; Uehira T; Shirasaka T
J Infect Chemother; 2012 Apr; 18(2):169-74. PubMed ID: 21968965
[TBL] [Abstract][Full Text] [Related]
14. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
[TBL] [Abstract][Full Text] [Related]
16. Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.
Rokx C; Alshangi H; Verbon A; Zietse R; Hoorn EJ; Rijnders BJ
J Infect Dis; 2016 Feb; 213(4):561-8. PubMed ID: 26401025
[TBL] [Abstract][Full Text] [Related]
17. Switching from tenofovir containing regimens to boosted protease inhibitor monotherapy: Impact on renal function.
Estébanez M; Bernardino JI; Serrano L; Pérez-Valero I; Zamora FX; Montes-Ramírez ML; González-García JJ; Arribas JR
Enferm Infecc Microbiol Clin; 2016 Jan; 34(1):29-32. PubMed ID: 25735716
[TBL] [Abstract][Full Text] [Related]
18. Acute Kidney Injury, Risk Factors, and Prognosis in Hospitalized HIV-Infected Adults in South Africa, Compared by Tenofovir Exposure.
Seedat F; Martinson N; Motlhaoleng K; Abraham P; Mancama D; Naicker S; Variava E
AIDS Res Hum Retroviruses; 2017 Jan; 33(1):33-40. PubMed ID: 27478997
[TBL] [Abstract][Full Text] [Related]
19. Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate.
Medland NA; Chow EP; Walker RG; Chen M; Read TR; Fairley CK
Int J STD AIDS; 2018 Mar; 29(3):227-236. PubMed ID: 28764611
[TBL] [Abstract][Full Text] [Related]
20. Administration of tenofovir disoproxil fumarate-based antiretroviral therapy in an HIV-infected patient following unilateral nephrectomy.
Biagi M; Badowski M; Chiampas T; Young J; Vaughn P; Shicker L; Patel M
Int J STD AIDS; 2016 Aug; 27(9):808-11. PubMed ID: 26378193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
